Navigation Links
Bionovo Announces 2010 Highlights and Year-End Financial Results
Date:3/15/2011

and metabolic syndrome.
  • In July, Bionovo entered into a $15 million, at-the-market firm commitment financing agreement with Aspire Capital. Although the Company has not yet accessed this facility, it is still available under the original conditions. Further, Aspire Capital participated in the underwritten offering that closed in February, 2011.
  • The Company also announced additions to its network of advisors and consultants, including leading healthcare professionals with extensive experience in the development of therapeutic treatments:
  • Dr. Richard Weiner, PhD, Emeritus Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences, at the University of California, San Francisco.
  • Dr. Paul Pui-Hay But, PhD, Chief Scientist for the Food and Drug Authentication Laboratory Ltd., Hong Kong, China.

  • Full Year ResultsFor the year ended December 31, 2010 total revenues were $0.6 million compared with $0.3 million for the same period in 2009. Revenues in 2010 consisted of a Qualifying Therapeutic Discovery Project Credit of $0.5 million and $0.1 million in a National Institute of Health (NIH) grant drawdown.  Revenue in 2009 was comprised of approximately $55,000 in limited research services revenue combined with $0.2 million in NIH grant drawdown.

    For the year ended December 31, 2010 total operating expenses were $18.2 million compared with $16.6 million for the same period in 2009. The increase in 2010 operating expenses were primarily due to additional expenses to support our Menerba manufacturing process development.

    The net loss for the year ended December 31, 2010 was $17.7 million, or $0.80 per share, compared with a net loss of $16.4 million, or $0.98 per share, for the same period in 2009. The year-over-year increase in net loss was driven primarily by the expenses related to the Menerba manufacturing process development and 2010 director and employee performance bonuse
    '/>"/>

    SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Bionovo, Inc. to Announce Fourth Quarter Fiscal Year 2010 Financial Results on Tuesday, March 15, 2011
    2. Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference
    3. Bionovo Announces 2011 Plan of Action on MF101 (Menerba™)
    4. Bionovo Announces Pricing of Follow-on Offering of Common Stock and Warrants
    5. Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
    6. Bionovo Releases FDA-Approved Clinical Development Plan for Menerba
    7. Bionovo Announces Publication Describing Estrogen Receptor Beta Cancer Prevention Mechanism
    8. Bionovo Announces Third Quarter 2010 Highlights and Financial Results
    9. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2010 Financial Results on Thursday, November 11, 2010
    10. Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions
    11. Bionovo to Raise $3 Million Through Registered Direct Offering
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... and RALEIGH, N.C. , ... of Endo International plc (NASDAQ: ENDP ) ... BDSI ) announced today that they have submitted ... Film to the U.S. Food and Drug Administration (FDA).  ... management of pain severe enough to require daily, around-the-clock, ...
    (Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
    (Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
    Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
    ... VirtualScopics, Inc. (Nasdaq: VSCP ), a ... today that Ms. Molly Henderson, the company,s chief business ... at the Rodman & Renshaw Healthcare Conference at the ... will be on Tuesday, September 14, 2010 at 11:40am ...
    ... 8 Dyadic International, Inc. ("Dyadic") (Pink Sheets: ... the discovery, development, manufacture and sale of specialty enzyme ... biopharmaceutical industries, today announced that its President and Chief ... Rodman & Renshaw Annual Global Investment Conference at ...
    Cached Medicine Technology:VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference 2Dyadic International and EnGen Bio to Present at Rodman & Renshaw Annual Global Investment Conference 2
    (Date:12/25/2014)... (PRWEB) December 26, 2014 The ... CAGR of 7.2% to reach $5,756.0 million by ... the microscopy market. The electron microscopes product segment ... the forecast period. , Rising focus on nanotechnology, ... growth of the microscopy market. , Get Full ...
    (Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
    (Date:12/25/2014)... 2014 “Every three months the trends for ... sweetheart evening dress will be one of the hottest styles ... Yunx.co.uk says. Today, the company releases 26 A-line sweetheart evening ... 80% off. , “We are trying our best to ... our latest designs. Along with affordable prices, we provide discounted ...
    (Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
    (Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
    Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
    ... in Ongoing Research to Replicate Insulin-Producing Function of Healthy ... SANTA BARBARA, Calif., March 31 A key step ... patients with diabetes has been achieved, according to new ... Technology & Therapeutics .Researchers at the University of ...
    ... refractory patients recruited in trial;, ... complete efficacy data to be available in ... Life Sciences Inc. (TSX: BNC), a research-based, technology-driven ... completed recruitment in its initial Phase III registration ...
    ... in The Journal of Nursing Administration shows ... continuous vigilance monitoring is used on medical-surgical unit beds. ... President and CEO of Hoana Medical, Inc. "Using ... potential patient deterioration so they can respond appropriately. ...
    ... magazine for medical device makers appoints Full Spectrum Software’s Andrew Dallas ... premier magazine for the medical device industry has appointed Andrew Dallas ... president and CTO of Full Spectrum Software company background ... ...
    ... Urgent Care Center. Hoboken residents now have much needed option for treatment ... ... -- Hoboken families now have a convenient place to go for most ... Hoboken,s first Urgent Care center and a medical facility like no other ...
    ... ... Alpharetta, Ga. (PRWEB) March 31, 2009 -- Among 1,239 ... had not worked at a government healthcare facility at least once. ... in trying government locum tenens jobs. This is good news ...
    Cached Medicine News:Health News:Researchers Successfully Create Computer-Simulated Model for Evaluating Artificial Pancreas 2Health News:Researchers Successfully Create Computer-Simulated Model for Evaluating Artificial Pancreas 3Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 2Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 3Health News:Continuous Vigilance Monitoring Technology Benefits Nurses & Patients 2Health News:Andrew Dallas, President of Full Spectrum Software Appointed to Medical Device and Diagnostic Industry Magazine Editorial Advisory Board 2Health News:PromptMD Announces the Opening of their First Urgent Care Center at 309 First Street in Hoboken 2Health News:Physician Survey Highlights Advantages of Government Locum Tenens Jobs 2Health News:Physician Survey Highlights Advantages of Government Locum Tenens Jobs 3
    ... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
    ... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
    ... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
    ... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
    Medicine Products: